The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis

AIDS

Volumn 22, Issue 15, 2008, Pages 1919-1927

  Gupta, Samir K ^a,f   Rosenkranz, Susan L ^b   Cramer, Yoninah S ^b   Koletar, Susan L ^c   Szczech, Lynda A ^d   Amorosa, Valerianna ^e   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

Dialysis; Efavirenz; HIV; Lopinavir; Pharmacogenomics; Pharmacokinetics; Renal failure; Ritonavir

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARAMETER; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PYRIMIDINONES; RENAL DIALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 53549114197     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830e011f     Document Type: Article

References (28)

1. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of antiretroviral drugs in hemodialysis. Kidney Int 2001; 60:821-830.
2. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993; 71:282-290.
3. Kanfer A, Stamatakis G, Torlotin JC, Fredj G, Kenouch S, Mery JP. Changes in erythromycin pharmacokinetics induced by renal failure. Clin Nephrol 1987; 27:147-150.
4. Ahmed JH, Grant AC, Rodger RS, Murray GR, Elliott HL. Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991; 32:57-62.
5. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28:1317-1320.
6. Veau C, Leroy C, Banide H, Auchere D, Tardivel S, Farinotti R, et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant 2001; 16:1607-1614.
7. Boobis SW. Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther 1977;22:147-153.
8. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
9. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003; 8:531-534.
10. Frohlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE. Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 2004; 58:443-444.
11. Ernest CS 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005; 312:583-591.
12. Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF, et al. A multiinvestigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clinical Trials 2003; 4:287-300.
13. Yeh KC, Kwan KC. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 1978; 6:79-98.
14. FDA Guidance for Industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. US Health and Human Services FDA, CDER, CBER; November, 1999.
15. Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, et al. Lopinavir protein binding in vivo through the 12-h dosing interval. Ther Drug Monit 2004; 26:35-39.
16. Izzedine H, Aymard G, Launay-Vacher V, Hamani A, Deray G. Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis. AIDS 2000; 14:618-619.
17. Das S, Ghanem M, Huengsberg M. Experience with efavirenz in end-stage renal disease. Int J STD AIDS 2004; 15:143.
18. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40:1358-1361.
19. US Renal Data System. USRDS 2005 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases; 2007.
20. Nunez M, Gonzalez de Requena D, Gallego L, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001; 28:399-400.
21. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
22. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003; 17:1696-1698.
23. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 2003; 34:295-298.
24. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
25. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1 : a pharmacogenetics study. Lancet 2002; 359:30-36.
26. Izzedine H, Launay-Vacher V, Legrand M, Lieberherr D, Caumes E, Deray G. ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis. AIDS 2001; 15:662-664.
27. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5:243-272.
28. Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189:265-272.